Pegloticase
Pegloticase ‘effectively and expeditiously’ leads 47% of gout patients into remission
Nearly half of patients with gout achieved remission with pegloticase treatment by 52 weeks, indicating longer-term benefits for intensive urate-lowering therapy, according to data presented at EULAR 2024 Congress.
Patients with gout treated with pegloticase, methotrexate have lower blood pressure
PHILADELPHIA — Pegloticase and methotrexate can be used to reduce blood pressure in patients with gout, hinting at a link between serum uric acid level and hypertension, according to data presented at the ASN Kidney Week conference.
Adding methotrexate to pegloticase for gout increases response rate through 52 weeks
Patients who receive pegloticase alongside methotrexate for gout demonstrate higher response rates and fewer discontinuations, and were more likely to achieve tophi resolution, vs. those treated with pegloticase alone, according to data.
Amgen clear to acquire Horizon after agreement with Federal Trade Commission
Amgen has reached a deal with the Federal Trade Commission that will enable the pharmaceutical company to complete its $28 billion acquisition of Horizon, according to statements from both parties.
Federal Trade Commission sues to block Amgen’s acquisition of Horizon
The Federal Trade Commission has sued to stop Amgen from acquiring Horizon Therapeutics, a potential blockbuster deal that could restrict marketplace competition, according to an FTC press release.
Trial results show gout therapy of pegloticase, methotrexate maintained eGFR vs. placebo
AUSTIN, Texas —Results from a poster presentation here showed that patients with uncontrolled gout treated with the combined therapy of pegloticase and methotrexate saw a reduction in gout symptoms as well as a stable eGFR.
Methotrexate plus pegloticase superior to pegloticase alone in gout
Adding methotrexate to pegloticase increased treatment response, compared with pegloticase alone, in patients with uncontrolled gout, according to data published in Arthritis & Rheumatology.
VIDEO: Pegloticase, methotrexate treats uncontrolled gout without compromising kidney
ORLANDO — In this video from ASN Kidney Week, Abdul A. Abdellatif, MD, discusses the efficacy of pegloticase treatment in conjunction with methotrexate for patients with uncontrolled gout.
FDA approves pegloticase, methotrexate combo in patients with uncontrolled gout
The FDA has approved the supplemental biologics license application for pegloticase, expanding the drug’s label to include co-administration with methotrexate in patients with uncontrolled gout, according to a press release.
Q&A: Pegloticase sustained lower serum urate in kidney transplant recipients with gout
Among kidney transplant recipients with uncontrolled gout, pegloticase showed sustained decreased serum urate levels, according to findings presented at the American Transplant Congress.